Supporting these findings, the phase II MAYA trial (NCT03832621) administrated two cycles of TMZ followed by a combination of ipilimumab and nivolumab in patients with chemo-refractory MSS CRC and MGMT silencing, yielding an improved ORR of 45%, an 8-month PFS rate of 36%, and an OS of 18.4 months (239). This evidence concerns the gene MGMT and colorectal carcinoma.